Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

6K0J

The co-crystal structure of DYRK2 with a small molecule inhibitor

Summary for 6K0J
Entry DOI10.2210/pdb6k0j/pdb
DescriptorDual specificity tyrosine-phosphorylation-regulated kinase 2, 3-(2,7-dimethoxyacridin-9-yl)sulfanylpropan-1-amine (3 entities in total)
Functional Keywordskinase, transferase-inhibitor complex, transferase/inhibitor
Biological sourceHomo sapiens (Human)
Total number of polymer chains1
Total formula weight38099.10
Authors
Tiantian, W.,Xiao, J. (deposition date: 2019-05-06, release date: 2019-11-20, Last modification date: 2024-11-13)
Primary citationBanerjee, S.,Wei, T.,Wang, J.,Lee, J.J.,Gutierrez, H.L.,Chapman, O.,Wiley, S.E.,Mayfield, J.E.,Tandon, V.,Juarez, E.F.,Chavez, L.,Liang, R.,Sah, R.L.,Costello, C.,Mesirov, J.P.,de la Vega, L.,Cooper, K.L.,Dixon, J.E.,Xiao, J.,Lei, X.
Inhibition of dual-specificity tyrosine phosphorylation-regulated kinase 2 perturbs 26S proteasome-addicted neoplastic progression.
Proc.Natl.Acad.Sci.USA, 116:24881-24891, 2019
Cited by
PubMed Abstract: Dependence on the 26S proteasome is an Achilles' heel for triple-negative breast cancer (TNBC) and multiple myeloma (MM). The therapeutic proteasome inhibitor, bortezomib, successfully targets MM but often leads to drug-resistant disease relapse and fails in breast cancer. Here we show that a 26S proteasome-regulating kinase, DYRK2, is a therapeutic target for both MM and TNBC. Genome editing or small-molecule mediated inhibition of DYRK2 significantly reduces 26S proteasome activity, bypasses bortezomib resistance, and dramatically delays in vivo tumor growth in MM and TNBC thereby promoting survival. We further characterized the ability of LDN192960, a potent and selective DYRK2-inhibitor, to alleviate tumor burden in vivo. The drug docks into the active site of DYRK2 and partially inhibits all 3 core peptidase activities of the proteasome. Our results suggest that targeting 26S proteasome regulators will pave the way for therapeutic strategies in MM and TNBC.
PubMed: 31754034
DOI: 10.1073/pnas.1912033116
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (2.352 Å)
Structure validation

248636

PDB entries from 2026-02-04

PDB statisticsPDBj update infoContact PDBjnumon